Personalized myeloma treatment based on response and fitness
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether tailoring myeloma treatment based on how well you respond to initial therapy and your overall health status can improve outcomes. You'll receive standard first-line treatment (three drugs: daratumumab, lenalidomide, and dexamethasone) and then be assigned to a personalized pathway based on your response and fitness level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed with symptomatic myeloma (a blood cancer affecting plasma cells)
- Not suitable for stem cell transplant as determined by your doctor
- Planned to receive daratumumab, lenalidomide, and dexamethasone as first-line treatment
- Age 18 or older
- Able to provide informed consent and follow a pregnancy prevention plan
- No previous myeloma treatment (except as specified in the study protocol)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this approach can better control the disease.
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
This trial tests two different combinations of medicines in people who still have signs of multiple myeloma after a stem cell transplant. One group gets teclistamab and talquetamab, and the other gets daratumumab and lenalidomide. The goal is to see which works better at removing any remaining cancer cells.
This study looks at how newly diagnosed myeloma patients in the UK respond to a specific drug combination (daratumumab, lenalidomide, and dexamethasone) when used as first-line treatment. Researchers want to understand how well this treatment works in everyday practice, outside of controlled clinical trials.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.